Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631559 | 0.94 | ESR1 (0.49) | ESR1NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL13433471 | 0.93 | GRM5 (0.51) | GRM5ESR1NR1H3MEN1KMT2A | |
| SCHEMBL2625350 | 0.92 | GRM5 (0.48) | GRM5ESR1MEN1KMT2AALDH1A1 | |
| SCHEMBL16937189 | 0.90 | GRM5 (0.51) | GRM5ESR1NR1H3MEN1KMT2A | |
| SCHEMBL2710552 | 0.90 | ESR1 (0.50) | ESR1NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL2624624 | 0.88 | ESR1 (0.43) | ESR1NR1H3MEN1KMT2AALDH1A1 | |
| SCHEMBL7678431 | 0.87 | ESR1 (0.58) | GRM5ESR1NR1H3MEN1KMT2A | |
| SCHEMBL3447114 | 0.86 | GRM5 (0.46) | GRM5ESR1NR1H3MEN1KMT2A | |
| SCHEMBL10000450 | 0.86 | MAPK1 (0.53) | GRM5ESR1NR1H3MEN1KMT2A | |
| SCHEMBL6910583 | 0.86 | KMT2A (0.51) | GRM5ESR1NR1H3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303328-A1 | CROSS-LINKER | NEXAM CHEMICAL AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-20140303328-A1 | CROSS-LINKER | NEXAM CHEMICAL AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-8772418-B2 | Cross-linker | NEXAM CHEMICAL AB (SE) | 2014-07-08 | — | — | US | disclosed |
| US-8772418-B2 | Cross-linker | NEXAM CHEMICAL AB (SE) | 2014-07-08 | — | — | US | disclosed |
| EP-2630115-B1 | Crosslinking monomers for aliphatic polyamides | NEXAM CHEMICAL AB (SE) | 2014-05-14 | — | — | EP | disclosed |
| US-20130225769-A1 | CROSS-LINKER | NEXAM CHEMICAL AB (SE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225769-A1 | CROSS-LINKER | NEXAM CHEMICAL AB (SE) | 2013-08-29 | — | — | US | disclosed |
| EP-2444387-A1 | Cross-linkable end-cappers for primary amino groups | Nexam Chemical AB (SE) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303328-A1 | CROSS-LINKER | CAPZA2, PAPSS1, CHIA | GRM5 2202/4885ESR1 3681/4885NR1H3 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.